FDA warned SemaBio that its website sold compounded semaglutide and called it 'generic semaglutide,' a false or misleading claim.
What happened
FDA reviewed SemaBio's website at https://sema.bio in August 2025. FDA found the site offered compounded drug products, including semaglutide, and repeatedly used the claim 'generic semaglutide.' FDA says that claim is false or misleading because compounded drugs are not FDA-approved and the wording implies they are the same as an approved product.
What FDA found
The website repeatedly called compounded semaglutide 'generic semaglutide,' which falsely implies it is the same as an FDA-approved product.
FDCA sections 502(a) and 502(bb) [21 U.S.C. §§ 352(a), 352(bb)]Because of that claim, FDA says the compounded semaglutide products are misbranded drugs.
FDCA sections 502(a) and 502(bb) [21 U.S.C. §§ 352(a), 352(bb)]FDA says the misbranded products were introduced or delivered for introduction into interstate commerce.
FDCA section 301(a) [21 U.S.C. § 331(a)]FDA also says receiving misbranded drugs in interstate commerce, and delivering or offering to deliver them, is a violation.
FDCA section 301(c) [21 U.S.C. § 331(c)]
What FDA wants
FDA tells SemaBio to take immediate action, including stopping the misleading 'generic semaglutide' language, and to send a written response within 15 working days describing steps taken, how recurrence will be prevented, and related documentation.
Who should pay attention
- telehealth companies selling compounded semaglutide
- online pharmacies and compounding pharmacies
- marketing and compliance teams for drug websites
This is a summary. Read the original letter on fda.gov.